Literature DB >> 32591861

Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer.

Fan Zhang1,2, Hua Bai3, Ranran Gao1,2, Kailun Fei3, Jianchun Duan3, Zemin Zhang1,2, Jie Wang4, Xueda Hu5.   

Abstract

Understanding of the functional states and clonal dynamics of T cells after immune checkpoint blockade (ICB) is valuable for improving these therapeutic strategies. Here we performed Smart-seq2 single-cell RNA sequencing (scRNA-seq) analysis on 3,110 peripheral T cells of non-small cell lung cancer (NSCLC) patients before and after the initiation of programmed cell death protein 1 (PD-1) blockade. We identified individual peripheral T cell clones based on the full-length T cell receptor (TCR) sequences and monitored their dynamics during immunotherapy. We found a higher cytotoxic activity in the tumor-related CD4+ T cell clones than in the CD8+ T cell clones. Based on a large tumor-related CD4+ T cell clone, we observed a dramatically decreased abundance after progression, as well as a reduction in the percentage of PD-1+ T cells. We also detected 25 genes, such as CXCR4, DUSP2 and ZFP36, that were noticeably upregulated or downregulated following progression. In addition, the pseudotime trajectory of CD8+ T cell clones corresponded to the treatment time points, showing a decreased activity in the "cytokine and cytokine receptor interaction" pathway. These analyses provided an insight into the dynamics of peripheral T cell clones during PD-1 blockade in NSCLC.

Entities:  

Keywords:  Cancer immunotherapy; Non-small cell lung cancer; PD-1; Single cell sequencing

Year:  2020        PMID: 32591861     DOI: 10.1007/s00262-020-02642-4

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  6 in total

Review 1.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

Review 2.  The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer.

Authors:  Jingjing Qu; Quanhui Mei; Li Liu; Tianli Cheng; Peng Wang; Lijun Chen; Jianying Zhou
Journal:  Ther Adv Med Oncol       Date:  2021-02-15       Impact factor: 8.168

3.  Analysis of the Diagnosis Model of Peripheral Non-Small-Cell Lung Cancer under Computed Tomography Images.

Authors:  Zhonghai Xie; Huaizhong Zhang
Journal:  J Healthc Eng       Date:  2022-02-18       Impact factor: 2.682

Review 4.  Single-Cell RNA Sequencing in Lung Cancer: Revealing Phenotype Shaping of Stromal Cells in the Microenvironment.

Authors:  Jianhong Zhang; Chengyang Song; Ye Tian; Xueying Yang
Journal:  Front Immunol       Date:  2022-01-19       Impact factor: 7.561

Review 5.  High-throughput single-сell sequencing in cancer research.

Authors:  Qingzhu Jia; Han Chu; Zheng Jin; Haixia Long; Bo Zhu
Journal:  Signal Transduct Target Ther       Date:  2022-05-03

6.  Systemic Immune Dysregulation Correlates With Clinical Features of Early Non-Small Cell Lung Cancer.

Authors:  Zhixing Hao; Mingjie Lin; Feng Du; Zhongwei Xin; Dang Wu; Qun Yu; Yimin Wu; Zhouyu Zhu; Wenshan Li; Yongyuan Chen; Xiaoke Chen; Ying Chai; Shenghang Jin; Pin Wu
Journal:  Front Immunol       Date:  2022-01-18       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.